TrialJournal for immunotherapy of cancer2022

TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.

David B Rosen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.